The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Antimicrobial company Zoono (ZNO) has appointed Linco Investments as its exclusive distributor for Singapore
  • Singapore is an important market for Zoono as it is a recognised hub of the Association of Southeast Asian Nations country group
  • When applied, Zoono’s technology bonds with any surface on which it is applied to, then attracts and kills bacteria
  • The five-year distribution agreement will be available in all markets in Singapore
  • Under the deal, minimum purchase orders will start at $1.4 million
  • Zoono’s share price has jumped 24 per cent today with shares trading for $2.40 apiece

Zoono (ZNO) has appointed Linco Investments as its exclusive distributor for Singapore.

Linco Investments is a Singaporean based facilities and management company with roots dating back to 1988.

Linco’s group of companies are involved in the importation, distribution and supply to government agencies, private companies and business to consumer markets (B2C).

Singapore is an important market for Zoono as it is a recognised hub of the ASEAN (Association of Southeast Asian Nations) country group and a lot of companies’ head offices are located there.

Following the outbreak of the coronavirus, now named COVID-19, there continues to be exceptional interest in Zoono’s technology and its efficacy against bacteria and viruses.

Results from the German laboratory, testing the technology against the current strain of coronavirus, are expected soon.

When applied, Zoono’s technology leaves behind a mono-molecular layer that bonds with any surface on which it is applied to then attracts and destroys bacteria and pathogens.

Its ‘physical kill’ replaces the need for dangerous chemicals, poisons and alcohols, and the method of rupturing the cell means it cannot mutate, preventing the development of superbugs.

The distribution agreement is for an initial five-year term and its exclusive in all markets in Singapore.

Minimum purchase volumes include NZD$1.5 million (AUD$1.4 million) in the first 12 months, NZD$2 million (AUD$1.9 million) in year two, and NZD$2.6 million (AUD$2.4 million) in year three.

After this, the purchase volumes in the years following will increase by 10 per cent per annum.

Full payment is required for all the products before they are shipped and NZD$400,000 (AUD$383,699) has already been paid for its initial orders.

Zoono’s share price has jumped 19.4 per cent with shares trading for $2.31 apiece at 11:57 am AEDT.

ZNO by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…